Showing results (41-50 of 72) with videos related to
Sort By:
Pageof 8
Future Oncology (London, England)|January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceAlexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.Journal for Immunotherapy of Cancer|November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2021
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJessica S W Borgers, Richard P Tobin, Robert J Torphy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerUdai Banerji, D Ross Camidge, Henk M W Verheul, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Scott S Tykodi, Gregory A Daniels, et al.The New England Journal of Medicine|June 8, 2012
Efficacy and safety of vismodegib in advanced basal-cell carcinomaAleksandar Sekulic, Michael R Migden, Anthony E Oro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancerColin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.The Lancet. Oncology|May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialMichael R Migden, Alexander Guminski, Ralf Gutzmer, et al.Pageof 8